FX-322 in Adults With Age-Related Sensorineural Hearing Loss
Status:
Completed
Trial end date:
2021-02-24
Target enrollment:
Participant gender:
Summary
This is a Phase 1b, prospective, randomized, double-blind, placebo-controlled, single-dose,
multicenter, safety study of FX-322, administered by intratympanic injection, in adults with
age-related sensorineural hearing loss.